Genzyme Websites Genzyme Corporate

For U.S. Healthcare Professionals Only

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Contact my Rep

Open the Window of Opportunity

See Where Survival May Lead

JEVTANA significantly extended overall survival in patients with mHRPC after docetaxel.

  • 30% reduced risk of death with JEVTANA versus mitoxantrone (HR=0.70) (95% Cl: 0.59 - 0.83).
  • 15.1 months (95% CI: 14.1-16.3) median OS for patients receiving JEVTANA versus 12.7 months (95% CI: 11.6-13.7) with mitoxantrone (P<0.0001). Number of deaths 234 (62%) with JEVTANA versus 279 (74%) with mitoxantrone.
Learn More
 

Open the Window of Opportunity

JEVTANA significantly extended overall survival in patients with mHRPC after docetaxel

  • 30% reduced risk of death with JEVTANA versus mitoxantrone (HR=0.70) (95% Cl: 0.59 - 0.83).
  • 15.1 months (95% CI: 14.1-16.3) median OS for patients receiving JEVTANA versus 12.7 months (95% CI: 11.6-13.7) with mitoxantrone (P<0.0001). Number of deaths 234 (62%) with JEVTANA versus 279 (74%) with mitoxantrone.
Learn More
Show More

IMPORTANT SAFETY INFORMATION

You are leaving jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue Cancel